https://orcid.org/0000-0003-4369-6311
References
- Chen DM, Odueyungbo A, Csinady E, et al., French Study Group on Autoimmune Bullous Diseases. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182(5):1111–1119.
- Shakshouk H, Daneshpazhooh M, Murrell DF, et al. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol. 2020;82(6):e235–e236.
- Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–2040.
- Werth VP, Joly P, Mimouni D, et al. A phase III, randomized, double-blind, controlled study (PEMPHIX) to evaluate the efficacy and safety of rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. SKIN J Cutan Med. 2020;4(1):S26.
- Galimberti F, McBride J, Cronin M, et al. Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19. Clin Dermatol [Internet]. 2020;38(6):775–780.